Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesHLS Therapeutics Inc

HLS Therapeutics Inc

Healthcare Drug Manufacturers - Specialty & Generic
PortfolioPortfolio WatchlistWatchlist
Company price
4.22 CAD -0.01 ( 0.24%)
Last update at 2026-11-04T20:06:00Z
VOLUME
30198
Market Cap
145.42M

Momentum Score

…

HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products for the treatment of psychiatric disorders and cardiovascular disease in Canada, the United States, and internationally. The company offers Clozaril (clozapine tablets), an atypical antipsychotic to manage symptoms of treatment-resistant schizophrenia; CSAN Pronto device, which enhances and simplifies the mandatory safety blood monitoring process for patients that are prescribed Clozaril; Nilemdo, a bempedoic acid product for cardiovascular risk reduction; Nexlizet, a bempedoic acid and ezetimibe product for cardiovascular risk reduction; and Vascepa, an icosapent ethyl capsule for the treatment of cardiovascular disease. It also distributes MyCare psychiatry lab assays, which are a line of tests that can be processed on analyzers used in laboratory systems to measure the blood levels of the most common antipsychotic drugs, including clozapine, risperidone, quetiapine, aripiprazole, olanzapine, and paliperidone; and MyCare Insite, a point-of-care device that requires only a single drop of blood taken by a finger stick to measure patient drug levels. In addition, the company holds royalty interest in Takeda's Obizur, a porcine recombinant Factor VIII for acquired Hemophilia A. It serves wholesalers and institutions. HLS Therapeutics Inc. is headquartered in Etobicoke, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
4.22
Low
4.49
High
52 Week Price Range
4.17
Low
5.76
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

HLS Therapeutics Inc is a Canadian specialty pharmaceutical company that acquires, develops and commercializes prescription medicines for hospital and specialty markets. Long-term growth could be supported by expanding its branded portfolio through acquisitions and licensing, commercializing existing hospital products and launching in new markets. Investors may find the company attractive for its focused commercial model and recurring-revenue potential from on-market products.

Key risks include reliance on a small number of marketed products, regulatory and reimbursement uncertainty, competition from generics, and execution risk from acquisitions and expansion.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
4.23
Dividend Yield
-
Revenue TTM
55.50M
Revenue Per Share
1.76
Gross Profit TTM
39.71M
Debt / Equity
0.81
ROE
-18.69%
Net Debt
38.03M
ROCE
-3.76%
Diluted EPS TTM
-0.53

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -13.10M -15.58M -27.80M -23.72M -11.81M
Net income -12.65M -19.66M -27.53M -23.60M -13.12M
Selling general administrative 10.61M 10.20M 8.39M 17.73M 17.40M
Selling and marketing expenses 11.39M 16.73M 19.90M 17.85M 14.66M
Gross profit 24.01M 47.62M 55.45M 56.49M 56.04M
Reconciled depreciation 21.82M 22.72M 31.94M 34.40M 30.26M
Ebit -4.18M -5.50M -19.05M -13.44M -6.24M
Ebitda 18.02M 17.22M 12.88M 20.96M 24.02M
Depreciation and amortization 22.20M 22.72M 31.94M 34.40M 30.26M
Operating income -4.18M -7.69M -10.35M -13.44M -6.24M
Other operating expenses 60.65M 64.31M 63.07M 74.96M 66.29M
Interest expense 7.22M 10.08M 8.75M 7.32M 6.96M
Tax provision -0.45M 4.07M -0.27M -0.12M 1.31M
Interest income 0.11M 0.32M 0.35M 0.06M 0.04M
Net interest income -6.99M -9.76M -8.40M -7.26M -6.91M
Income tax expense -0.45M 4.07M -0.27M -0.12M 1.31M
Total revenue 56.47M 56.62M 63.07M 61.47M 60.01M
Total operating expenses 28.19M 55.31M 55.45M 69.98M 62.32M
Cost of revenue 32.46M 9.00M 7.62M 4.98M 3.97M
Total other income expense net -8.92M -7.90M -17.45M -10.28M -5.57M
Net income from continuing ops -12.43M -19.66M -27.53M -23.60M -13.12M
Net income applicable to common shares - -19.66M -27.53M -23.60M -13.12M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 137.28M 159.90M 209.06M 241.65M 275.90M
Intangible assets 105.43M 122.12M 162.34M 195.02M 229.18M
Other current assets 1.37M - 1.92M 3.56M 4.52M
Total liab 75.72M 88.56M 111.36M 116.33M 115.17M
Total stockholder equity 61.56M 71.34M 97.70M 125.32M 160.74M
Other current liab 10.85M 0.03M 1.72M 6.01M 5.75M
Common stock 255.87M - 262.13M 265.21M 265.92M
Capital stock 256.34M 260.60M 262.13M 265.21M 265.92M
Retained earnings -203.78M -194.18M -175.46M -148.45M -119.86M
Other liab - - - 1.38M 2.54M
Other assets - - - 1.13M 1.40M
Cash 11.70M 17.46M 21.95M 20.72M 21.18M
Cash and equivalents - - - 20.72M 21.18M
Total current liabilities 26.07M 22.55M 26.69M 31.19M 27.67M
Current deferred revenue - - 5.71M - -
Net debt 38.03M 48.11M 65.67M 76.62M 76.39M
Short term debt 4.81M - 5.16M 13.58M 12.61M
Short long term debt 4.33M 4.83M 4.69M 13.06M 12.00M
Short long term debt total 49.73M - 87.62M 97.34M 97.57M
Other stockholder equity 16.13M - 13.87M 13.82M 11.72M
Property plant equipment - - - 1.13M 1.57M
Total current assets 29.04M 35.40M 44.09M 44.37M 43.75M
Net tangible assets - - - -69.70M -68.44M
Net receivables 7.85M 6.72M 10.69M 11.19M 11.51M
Long term debt 44.45M 60.74M 82.05M 83.28M 84.13M
Inventory 8.12M 9.06M 9.53M 8.90M 8.93M
Accounts payable 10.42M 8.71M 14.11M 11.59M 9.32M
Accumulated other comprehensive income -6.67M - -2.84M -5.26M 2.96M
Non currrent assets other 0.33M 0.53M 0.62M 0.67M 0.71M
Non current assets total 108.24M 124.50M 164.97M 197.28M 232.15M
Capital lease obligations 1.04M 0.88M 0.88M 1.01M 1.43M
Long term debt total - - - 83.76M 84.96M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - 11.73M -0.19M -10.15M -4.51M
Change to liabilities - - - 3.24M -3.65M
Total cashflows from investing activities -1.73M 11.73M -0.19M -10.15M -4.51M
Net borrowings -18.37M -21.57M -9.46M -0.44M -11.14M
Total cash from financing activities -20.52M -23.36M -14.64M -6.86M -11.40M
Change to operating activities - - - -0.71M -1.74M
Net income -12.65M -19.66M -27.53M -23.60M -13.12M
Change in cash -6.58M -4.50M 1.23M -0.46M 0.57M
Begin period cash flow 18.28M 21.95M 20.72M 21.18M 20.61M
End period cash flow 11.70M 17.46M 21.95M 20.72M 21.18M
Total cash from operating activities 16.02M 8.00M 15.79M 16.94M 16.43M
Depreciation 22.20M 22.72M 31.94M 34.40M 30.26M
Other cashflows from investing activities - 13.25M -0.15M -10.00M -3.82M
Dividends paid - 0.00M -2.40M 4.96M 5.12M
Change to inventory 1.30M -0.19M -0.66M -0.62M 1.77M
Change to account receivables 0.00M 2.37M 0.63M -0.07M 1.04M
Sale purchase of stock -1.83M -0.60M -1.55M -1.00M -0.05M
Other cashflows from financing activities -0.62M -1.19M -1.23M 9.54M 4.91M
Change to netincome - - - 4.59M 2.30M
Capital expenditures 0.21M 0.01M 0.19M 10.15M 4.51M
Change in working capital 4.82M 1.14M 5.04M 1.55M -3.02M
Stock based compensation 1.91M 1.62M -0.54M 2.92M 2.35M
Other non cash items 2.97M -1.63M 7.58M 1.53M -1.19M
Free cash flow 15.81M 7.99M 15.60M 6.79M 11.92M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(CAD)
Price
(CAD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
HLS
HLS Therapeutics Inc		 -0.01
0.24%		 4.22 - 31.95 2.62 1.71 2.60 8.99
CURA
Curaleaf Holdings Inc.		 -0.74
5.20%		 13.49 - 138.89 2.57 3.14 2.47 13.10
BHC
Bausch Health Companies Inc		 0.31
2.72%		 11.72 13.98 1.35 0.28 18.74 2.12 6.84
CRON
Cronos Group Inc		 0.16
3.36%		 4.92 - 32.15 9.80 0.95 1.47 1.90
TLRY
Tilray Inc		 0.41
11.02%		 4.13 - 1000.00 1.28 0.53 1.08 -2.30

Profile*

HLS Therapeutics Inc

HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products for the treatment of psychiatric disorders and cardiovascular disease in Canada, the United States, and internationally. The company offers Clozaril (clozapine tablets), an atypical antipsychotic to manage symptoms of treatment-resistant schizophrenia; CSAN Pronto device, which enhances and simplifies the mandatory safety blood monitoring process for patients that are prescribed Clozaril; Nilemdo, a bempedoic acid product for cardiovascular risk reduction; Nexlizet, a bempedoic acid and ezetimibe product for cardiovascular risk reduction; and Vascepa, an icosapent ethyl capsule for the treatment of cardiovascular disease. It also distributes MyCare psychiatry lab assays, which are a line of tests that can be processed on analyzers used in laboratory systems to measure the blood levels of the most common antipsychotic drugs, including clozapine, risperidone, quetiapine, aripiprazole, olanzapine, and paliperidone; and MyCare Insite, a point-of-care device that requires only a single drop of blood taken by a finger stick to measure patient drug levels. In addition, the company holds royalty interest in Takeda's Obizur, a porcine recombinant Factor VIII for acquired Hemophilia A. It serves wholesalers and institutions. HLS Therapeutics Inc. is headquartered in Etobicoke, Canada.

10 Carlson Court, Etobicoke, ON, Canada, M9W 6L2

647-495-9000

https://www.hlstherapeutics.com

85

Name Title Year Born
Mr. Gregory David Gubitz B.A., L.L.B., LL.B Co-Founder & Chairman 1957
Mr. Gilbert Godin Co-Founder, CEO & Director 1959
Mr. Tim Hendrickson M.B.A. Chief Financial Officer 1972
Mr. Sanjiv Sharma Chief Commercial Officer 1956
Mr. Ryan C. Lennox B.A., J.D. Sr. VP of Legal, HR & Compliance and Corp. Sec. 1981
David Spence Corp. Controller 1968
Mr. Craig Stuart Millian M.B.A. CEO & Director 1968
Mr. John Hanna CPA, CGA, M.B.A. CFO & Non-Independent Director 1965
Dr. Jason A. Gross Pharm.D. Vice President of Scientific Affairs 1965
Mr. Ryan C. Lennox B.A., J.D. Senior VP of Legal, HR & Compliance and Corporate Secretary 1981

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

PRL
CAD 30.50
+15.05%
DSV
CAD 11.02
+14.55%
USA
CAD 4.29
+13.19%
NUAG
CAD 7.70
+12.90%
GMIN
CAD 43.79
+12.86%
DRUG
CAD 26.11
-29.58%
HUT
CAD 68.98
-22.41%
UCU
CAD 2.09
-14.34%
VET
CAD 14.87
-14.29%
PHX
CAD 10.96
-13.56%

Equity Sectors*

  • Basic Materials

    +5.46%

  • Communication Services

    +3.38%

  • Consumer Cyclical

    +3.11%

  • Consumer Defensive

    +1.35%

  • Energy

    -4.79%

  • Financial Services

    +2.66%

  • Healthcare

    -0.72%

  • Industrials

    -0.11%

  • Real Estate

    +1.84%

  • Technology

    +1.05%

  • Utilities

    +0.39%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…